Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q1 2027 · 10-Q
Revenue$1.48M$1.48M+504.9% vs Q1 2026 Net Income-$13.03M-$13.03MN/M vs Q1 2026 EPS Diluted-$0.30-$0.30N/M vs Q1 2026 Operating Income-$13,348,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
Margins · derivedOperating margin-904.3%+5572.7 pt vs Q1 2026
Net margin-882.8%+5303.7 pt vs Q1 2026
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end